SCHEMBL30775381

SCHEMBL30775381

O=C1NCc2c1cccc2-c1ccncc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 3/20 0.49
CDK5 Q00535 2/20 0.49
DYRK1A Q13627 2/20 0.49
PIM1 P11309 1/20 0.49
CSNK1A1 P48729 1/20 0.49
ROCK1 Q13464 1/20 0.49
LRRK2 Q5S007 1/20 0.49
DYRK1B Q9Y463 1/20 0.49
PIK3CD O00329 3/20 0.48
PIK3CB P42338 3/20 0.48
PIK3CA P42336 2/20 0.48
LTK P29376 1/20 0.47
MST1R Q04912 1/20 0.47
KDR P35968 6/20 0.46
CDC7 O00311 2/20 0.46
ROCK2 O75116 1/20 0.42
MAP4K4 O95819 1/20 0.42
PRKACA P17612 1/20 0.42
CDK2 P24941 1/20 0.42
GSK3B P49841 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28223905 0.82 CLK4 (0.56) CLK4CDK5DYRK1APIM1CSNK1A1
SCHEMBL30775196 0.82 CLK4 (0.49) CLK4CDK5DYRK1APIM1CSNK1A1
SCHEMBL30775271 0.81 CLK4 (0.45) CLK4CDK5DYRK1APIM1CSNK1A1
SCHEMBL1078443 0.77 CDK5 (0.61) CLK4CDK5DYRK1APIM1CSNK1A1
SCHEMBL29871952 0.77 CDK5 (0.61) CLK4CDK5DYRK1APIM1CSNK1A1
SCHEMBL29845432 0.76 CLK4 (0.57) CLK4CDK5DYRK1APIM1CSNK1A1
SCHEMBL30775251 0.75 CLK4 (0.51) CLK4CDK5DYRK1APIM1CSNK1A1
SCHEMBL30775186 0.75 PARP10 (0.56) CLK4CDK5DYRK1APIM1CSNK1A1
SCHEMBL1334382 0.75 KDR (0.54) CLK4CDK5DYRK1APIM1CSNK1A1
SCHEMBL30775318 0.74 PIK3CD (0.63) CLK4CDK5DYRK1APIM1CSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR CLK4 3903/4885CDK5 1211/4885DYRK1A 4802/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR CLK4 3903/4885CDK5 1211/4885DYRK1A 4802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.